Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Treatment-for-herpes-virus

 Method of immunizing cats against shedding of Toxoplasma oocysts
I claim: 1. A method of immunizing a cat against shedding of Toxoplasma oocysts which comprises the ...


 Vaccine for immunizing cats against toxoplasma oocyst shedding
What is claimed is: 1. A method of immunizing cats against Toxoplasmosis without concomitant oocyst ...


 Attenuated viruses
We claim: 1. An attenuated poliovirus in which there is a reversal of a base pairing in the part, ...


 Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
OF THE INVENTION A fusion protein according to the invention includes NS1 and Rev proteins or ...


 Citrus peel extract as 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) reductase inhibitor
OF THE INVENTION The method of the present invention for inhibiting the activity of HMG-CoA in ...


 Heat shock-like protein
What is claimed is: 1. An isolated and purified polynucleotide sequence which encodes the heat ...


 Antiviral peptides
OF THE INVENTION While the specification concludes with claims particularly pointing out and ...


 Immunoglobulins devoid of light chains
We claim: 1. An immunoglobulin comprising two heavy polypeptide chains, each heavy chain consisting ...


 Buffered serum substitute for blood oxygen analyzer
What is claimed is: 1. A buffered serum substitute for receiving a blood sample, said serum ...


 Analytical method for determining volatiles, solids and solvent extractables
What is claimed is: 1. A method for determining amounts of volatiles, solids, and solvent ...


 Treatment for herpes virus

Details
Inventors: Tinnell, James E.;
Assignee:
Primary Examiner: Goldberg; Jerome D.
Assistant Examiner:
Attorney, Agent or Firm: Drummond; William H.

A treatment for herpes virus infections topical application of a suspension of tannic acid, and salicyclic acid, preferably in an ethanol solvent/carrier. After treatment, herpes lesions disappear within 4-5 days.

DETAILED DESCRIPTION OF THE INVENTION According to the invention, I provide a composition for and method of use of such composition, for the topic treatment of herpes virus lesions, which comprises about 2-12% wt tannic acid, 2-12% wt boric acid and about 1-6% wt salicylic acid, with the balance being a suitable liquid carrier such as, for example, ethanol.
Within the foregoing ranges, I prefer to employ about 2-7% wt tannic acid, 2-7% wt boric acid and 1-5% wt salicylic acid.
Higher concentrations are more effective, but may cause burning or irritation of sensitive mucosa; in particular, concentrations over 8% wt salicylic acid causes burning and discomfort.
Therefore, concentrations at the lower end of the preferred range are used for infections of the tongue, buccal or genital mucosa.
The compositions of the invention are clear solutions having about 7 to 14% by volume (settled) of solid particles, which are slurried by shaking prior to application.
Treatment is effected by applying a small quantity of the suspension directly to the lesions with a cotton swab, soft brush, or sponge.
Any quantity sufficient to cover the lesions with the suspension is effective.
Treatments are preferably applied 2 times per day for about three days.
With the more concentrated solutions, erythema, pain, and itching cease within four to twelve hours of the first application, and healing occurs in 48-72 hours.
In almost all cases, pain is substantially relieved in less than one hour from the first treatment.
All lesions clear in 4-5 days with little or no scarring.
If treatment begins on the first day when the patient notices the eruption, the infection will generally not reach the vesicular stage, and secondary infection and spreading to surrounding areas will not occur.
Very highh rates of successful remission of herpes virus on the external skin, tongue, buccal mucosa, and genitalia have been obtained with treatment in accordance with the invention.
This treatment is not recommended for herpes infections of the eye, since the acidity of the suspension would cause burning of the eye tissues



Related patents
  Microbicidal meta oxy- and thio-substituted phenylanilines
What is claimed is: 1. A compound of the formula I, including salts and metal complexes thereof ##STR52## wherein R.sub.1 and R.sub.2 independently of one another are ...
  Synergistic microbiocidal composition containing a mixture of a bicyclic polyoxymethyleneoxazolidine and an acroloin/formaldehyde polycondensation product
We claim: 1. A microbiocidal composition comprising a synergistic mixture the first component of which is an acrolein/formaldehyde polycondensation product having a ...
  Substituted acyl derivatives of amino acids
OF THE INVENTION The invention in its broad aspects includes substituted acyl derivatives of amino acids having formula I above. The substituted acyl groups refer to ...
  Escherichia coliO-polysaccharide-protein conjugate vaccine
OF THE INVENTION The present invention relates to E. coli-protein conjugates for use in vaccines against E. coli. The present invention further relates to a method of ...
  Milk production
What is claimed is: 1. The method of improving rumen acetate/propionate ratios and milk production which is well known to be closely related to a high acetate/propionate ...
  Heterocyclic compounds, processes for their preparation and their use
We claim: 1. A compound of general formula (I): ##STR14## in which the amide function is in the 2 or 3 position on the thiophene ring, and wherein R.sub.1, R.sub.2, R....
  Virus insecticide compositions
What is claimed is: 1. A particulate insecticidal composition comprising a free-flowing particle mass containing 0.1 to 35 percent by weight of a finely divided virus ...
  Stable prostaglandin E group-containing formulation
OF THE INVENTION Now, as described above, thiol compounds, water-soluble high molecular weight compounds and/or water-soluble salts of deoxycholic acid are used as ...
  Medicinal facial mask
OF THE INVENTION The compositions of the present invention comprise a pharmaceutically and cosmetically acceptable formulations in which up to 20% by volume of an acid ...
  p75 TNF receptor promoters
OF THE INVENTION A human genomic library containing the human p75 TNF-R was obtained from Stratagene. This library was a phage library, from which 8 phages were ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved